H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $90 from $85 and keeps a Buy rating on the shares. The firm anticipates that Ohtuvayre sales should be incrementally higher than originally forecast, given the lower level of competition in the wake of potential delays to the approval and market entry of itepekimab.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $107 from $93 at Wells Fargo
- Biotech Alert: Searches spiking for these stocks today
- Verona Pharma price target raised to $92 from $83 at Roth Capital
- Verona Pharma price target raised to $90 from $83 at BTIG
- Verona Pharma price target raised to $106 from $72 at Canaccord